Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population
Journal of Cachexia, Sarcopenia and Muscle · 2025
DOI: 10.1002/jcsm.13848 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Limy Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Monash University Eastern Health Clinical School, Victoria, Australia. Hauptthemen laut MEDLINE: Sarcopenia, Renal Dialysis, Fibroblast Growth Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2021 and 2022 Royal Australasian College of Physicians Jacquot Research Establishment Fellowship, APH Philanthropic Foundation Research and Innovation Grant.
Abstract (Originalsprache)
Background
Sarcopenia is defined as the loss of muscle mass, strength, and/or performance. It is strongly associated with all‐cause mortality. Fibroblast growth factor 23 (FGF23) is markedly elevated in patients with chronic kidney disease, especially those receiving maintenance dialysis. FGF23 has previously been shown to have a direct role in cardiac dysfunction mediated through left ventricular hypertrophy. However, its role in the development of (or protection from) sarcopenia is uncertain. This study is aimed at determining the relationship between FGF23 and muscle‐related parameters and to assess the effect of FGF23 on skeletal muscle myoblasts.
Methods
A single centre, cross‐sectional study examining maintenance haemodialysis patients was conducted. Sarcopenia was defined in accordance with the revised European Working Group on Sarcopenia in Older People and the Asian Working Group for Sarcopenia criteria. Clinical assessment methods included bioelectrical impedance analysis, anthropometric measurement, handgrip strength and physical performance appraisal. Both intact FGF23, which is biologically active, and the inactive C‐terminal FGF23 were measured using enzyme‐linked immunosorbent assays. The direct effects of FGF23 on skeletal muscle myoblast proliferation and myogenic differentiation were assessed using an in vitro culture system. Linear and logistic regression analyses were performed to examine the associations between FGF23 and muscle‐related parameters and sarcopenia, respectively.
Results
Eighty‐one patients were included with a median age of 75 years (interquartile range 67–80), and 63% were male. Log‐transformed serum FGF23 correlated positively with handgrip strength ( r = 0.27, p = 0.01, 95% confidence interval (CI) 0.06–0.46) and calf circumference ( r = 0.27, p = 0.01, 95% CI 0.06–0.46), and in multiple regression analyses, it was found to be a significant independent predictor of both handgrip strength (beta = 5.39, 95% CI 2.07–8.72) and sarcopenia (odds ratio = 0.14, 95% CI 0.02–0.75). FGF23 was found to promote myoblast proliferation but attenuate myogenic differentiation. At 48 h of differentiation, the expressions of MyoG and MyoD were significantly lower in cells treated with FGF23 than the control. The fusion index and myotube diameters were reduced on Day 7 of differentiation in FGF23‐treated cells compared to the control.
Conclusions
Higher serum FGF23 levels were associated with stronger handgrip strength and lower odds of having sarcopenia in maintenance haemodialysis patients. Our findings suggest that supraphysiological levels of FGF23 might play a role in muscle regeneration by promoting myoblast proliferation but repressing myogenic differentiation to support the expansion of the proliferative pool. FGF23 could potentially serve as a serum biomarker for muscle health in dialysis populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Renal Medicine, Monash University Eastern Health Clinical School, Victoria, Australia.
- Department of Renal Medicine, Eastern Health, Victoria, Australia.
- Eastern Health Clinical School, Monash University, Victoria, Australia.
ORCID-Profile: Limy Wong
Förderung
- 2021 and 2022 Royal Australasian College of Physicians Jacquot Research Establishment Fellowship
- APH Philanthropic Foundation Research and Innovation Grant
Zitieren
APA
Wong, L., Kenny, R., Ooi, J. Y. Y., Tsang, Y. S., Schembri, E., & McMahon, L. P. (2025). Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13848
Vancouver
Wong L, Kenny R, Ooi JYY, Tsang YS, Schembri E, McMahon LP. Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13848
BibTeX
@article{Wong2025,
author = {Wong, Limy and Kenny, Rachel and Ooi, Jenny Y Y and Tsang, Yung Shing and Schembri, Emily and McMahon, Lawrence P},
title = {Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
doi = {10.1002/jcsm.13848}
}
EUVIMED